Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This study has been important in establishing synthetic human parathyroid hormone 1-34 (PTH)
as a beneficial treatment for hypoparathyroidism, superior to conventional therapy with
calcium and calcitriol. Providing synthetic human parathyroid hormone 1-34 (PTH) to patients
who are unresponsive to conventional therapy has enabled severe cases of hypoparathyroidism
to be managed effectively with the investigational drug, PTH. The primary goals of this study
are to (1) provide long-term PTH therapy to patients who do not respond to conventional
therapy; (2) understand the long-term effect of therapeutic PTH replacement on kidney
function and bone mineral density; (3) study and track linear growth and bone accrual in
children with hypoparathyroidism. (4) determine if subjects reach a normal level of peak bone
mass and if the timing of this is comparable to normal age-matched healthy controls.
Phase:
Phase 2
Details
Lead Sponsor:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Treatments:
Calcitriol Calcium Calcium, Dietary Hormones Parathyroid Hormone Vitamin D Vitamins